IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 247 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $100,752,789 | -29.8% | 22,143,470 | +8.6% | 0.00% | -33.3% |
Q2 2023 | $143,583,532 | +73.6% | 20,395,388 | +50.6% | 0.00% | +50.0% |
Q1 2023 | $82,730,189 | -10.5% | 13,540,129 | -6.4% | 0.00% | -33.3% |
Q4 2022 | $92,419,094 | -32.3% | 14,463,082 | +1.5% | 0.00% | -25.0% |
Q3 2022 | $136,551,000 | -7.4% | 14,253,754 | +6.7% | 0.00% | 0.0% |
Q2 2022 | $147,529,000 | -28.2% | 13,363,027 | +8.3% | 0.00% | -20.0% |
Q1 2022 | $205,489,000 | -11.8% | 12,341,653 | +1.2% | 0.01% | 0.0% |
Q4 2021 | $232,856,000 | -20.8% | 12,197,787 | +2.3% | 0.01% | -28.6% |
Q3 2021 | $294,169,000 | -7.6% | 11,928,989 | -2.5% | 0.01% | -12.5% |
Q2 2021 | $318,392,000 | -16.6% | 12,236,411 | +1.5% | 0.01% | -20.0% |
Q1 2021 | $381,614,000 | -30.7% | 12,053,487 | +1.6% | 0.01% | -37.5% |
Q4 2020 | $550,555,000 | +42.0% | 11,865,382 | +0.7% | 0.02% | +23.1% |
Q3 2020 | $387,750,000 | +15.5% | 11,778,527 | -3.7% | 0.01% | +8.3% |
Q2 2020 | $335,670,000 | +0.8% | 12,228,470 | +9.9% | 0.01% | -14.3% |
Q1 2020 | $333,153,000 | +10.9% | 11,129,211 | +2.5% | 0.01% | +40.0% |
Q4 2019 | $300,415,000 | +56.8% | 10,853,129 | +3.1% | 0.01% | +42.9% |
Q3 2019 | $191,613,000 | -8.0% | 10,528,180 | +24.0% | 0.01% | -12.5% |
Q2 2019 | $208,220,000 | +277.3% | 8,491,841 | +46.3% | 0.01% | +300.0% |
Q1 2019 | $55,185,000 | +7.9% | 5,802,878 | +0.4% | 0.00% | 0.0% |
Q4 2018 | $51,145,000 | +12.3% | 5,779,069 | +42.7% | 0.00% | 0.0% |
Q3 2018 | $45,550,000 | -5.0% | 4,048,782 | +8.1% | 0.00% | 0.0% |
Q2 2018 | $47,950,000 | -13.4% | 3,746,133 | +14.4% | 0.00% | 0.0% |
Q1 2018 | $55,362,000 | +151.4% | 3,275,856 | +19.0% | 0.00% | +100.0% |
Q4 2017 | $22,018,000 | +13.3% | 2,752,223 | +9.8% | 0.00% | 0.0% |
Q3 2017 | $19,428,000 | +20.6% | 2,506,839 | +14.4% | 0.00% | 0.0% |
Q2 2017 | $16,113,000 | – | 2,192,224 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ACUTA CAPITAL PARTNERS, LLC | 2,222,701 | $25,005,000 | 8.92% |
Broadfin Capital, LLC | 4,894,361 | $55,062,000 | 8.10% |
GREAT POINT PARTNERS LLC | 3,496,340 | $39,334,000 | 6.13% |
FRAZIER MANAGEMENT LLC | 2,188,331 | $24,619,000 | 4.51% |
Prosight Management, LP | 715,317 | $8,047,000 | 4.49% |
Avoro Capital Advisors LLC | 8,662,720 | $97,456,000 | 4.48% |
QVT Financial LP | 821,361 | $8,748,000 | 2.26% |
Perceptive Advisors | 7,290,199 | $82,014,000 | 2.19% |
Rhenman & Partners Asset Management AB | 1,290,495 | $14,518,000 | 1.46% |
EMORY UNIVERSITY | 185,915 | $2,092,000 | 1.37% |